Companies developing microbiome-based treatments have garnered a lot of interest recently, following many years of uncertainty over the approach. James McIlroy, 9 March 2022
Ever increasing investments are being made in artificial intelligence, as drugmakers spy an opportunity to drive efficiencies and spur innovation. In this episo 30 December 2021
In October 2016, Gabriel Baertschi left his role as president and general manager of AstraZeneca in Japan to take the top job at Germany’s Grünenthal Group. 27 October 2021
Getting celiac disease (CD) diagnosed can be a long and difficult path for patients, and with no effective treatments available, the outcome is often a burdenso 15 June 2021
Californian ageing specialist CohBar (Nasdaq: CWBR) is focused on treating mitochondrial diseases, but chief executive Steven Engle doesn’t rule out offering a 23 March 2021
Impressive data for another immuno-oncology / tyrosine kinase inhibitor (TKI) combo add up to yet more competition in the first-line kidney cancer setting. 21 September 2020
While vaccine developers including Moderna Therapeutics and AstraZeneca have reported promising results from their COVID-19 programs, the world urgently needs b 17 July 2020
Scientists have shown that inflammatory disease in the body is associated with an increased risk of Alzheimer’s, something that is central to the approach taken 17 February 2020
As biotech companies making themselves eligible to a big pharma buyout go, Imugene appears to tick a lot of the boxes – but the proof of the pudding will come w 24 January 2020
Biosimilars manufacturers can get a bad rap. Derided as offering mere copycats, piggybacking off the success of true innovators, companies such as South Korea's 6 December 2019
In March 2019, after a series of political convolutions worthy of a Choose Your Own Adventure novel, former UK Prime Minister Theresa May finally managed to bri 23 October 2019
As the dust settles on 2019’s annual meeting of the European Society of Medical Oncology (ESMO), data from several candidates give hope that the burden of disea 4 October 2019
Pivotal data from a Phase II study of the FGFR inhibitor pemigatinib will be used to support a US filing later in the year, says Incyte chief executive Hervé Ho 27 September 2019
In Cambridge, USA, just around the corner from fellow gene therapy specialist Bluebird Bio, a less well-known biotech startup could be about to shake up the mar 24 September 2019
Investors in the Atlas Venture-backed immuno-oncology specialist Surface Oncology (Nasdaq: SURF) have had a rough time since the company went public in New York 5 September 2019
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.